06/05/2026
Here at AHF UK, we stand with our colleagues at AHF in the U.S. to highlight this issue. When patents are extended, it can keep prices high and limit access to newer treatments that people need.
We urge Gilead Sciences shareholders to consider the real-world impact of these decisions. Because here in the UK, as everywhere, we believe that no patient’s health should be put on hold. Share this message if you support access to better HIV treatment without delay.”